HC Wainwright & Co. Maintains Buy on Sangamo Therapeutics, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio maintains a 'Buy' rating on Sangamo Therapeutics (NASDAQ:SGMO), but has lowered the price target from $5 to $3.
November 06, 2023 | 4:04 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sangamo Therapeutics' price target has been lowered from $5 to $3 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target for Sangamo Therapeutics by HC Wainwright & Co. indicates a potential decrease in the stock's value in the short term. However, the maintenance of the 'Buy' rating suggests that the analyst still sees potential in the company's long-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100